Age	Vaccine (No. of Doses)
At birth	BCG, vaccine against tuberculosis; trivalent oral polio vaccine (TOPV)
6 wk	TOPV (one); rotavirus vaccine (RV) oral (one); DTaP-IPV/Hib vaccine (one); hepatitis B vaccine (one); PCV7 pneumococcal vaccine (one)
10 wk	DTaP-IPV/Hib vaccine (two); DTaP (two); hepatitis B vaccine (two)
14 wk	RV, oral rotavirus vaccine (two); DTaP-IPV/Hib vaccine (three); hepatitis B vaccine (three); PCV₇, pneumococcal vaccine (two)
9 mo	Measles vaccine (one); PCV₇, pneumococcal vaccine (three)
18 mo	DTaP-IPV/Hib vaccine (four); measles vaccine (two)
6 yr	Td vaccine
12 yr	Td vaccine

BCG, Bacillus Calmette-Guérin; DTaP-IPV/Hib, Diphtheria and tetanus toxoids and acellular pertussis vaccine; Hib, Haemophilus influenzae type b, tetanus; IPV, inactivated polio vaccine; Td, vaccine against tetanus (lockjaw) with reduced strength of diphtheria.

From South African Vaccination and Immunisation Centre: www.savic.ac.za.

Table 16-2

Age	Vaccine
Birth	Hepatitis B (HepB) 1¹
1 mo	HepB 2²
2 mo	HepB 2, if not given at 1 mo; rotavirus vaccine (RV)²; diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP)³; Haemophilus influenzae type b conjugate vaccine (Hib)⁴; pneumococcal vaccine (PCV)⁵; inactivated poliovirus vaccine (IPV)⁶
4 mo	RV²; DTaP³; Hib⁴; PCV⁵; IPV⁶
6 mo	HepB 3 (6-18 mo)¹; RV²; DTaP³; Hib⁴; PCV⁵; IPV (6-18 mo)⁶; influenza yearly⁷ (6 mo-6 yr)
12 mo	Hib⁴; PCV⁵; measles, mumps, and rubella (MMR) (12-15 mo)⁸; varicella (12-15 mo)⁹; hepatitis A (HepA)¹⁰ (12-23 mo); second dose should be given 6-18 mo later
15 mo	DTaP³
18 mo	Influenza yearly⁷
2-3 yr	Influenza yearly⁷
4-6 yr	Influenza yearly⁷; DTaP³; IPV⁶; MMR⁸; varicella⁹

Note: Meningococcal conjugate vaccine, quadrivalent (MCV4), minimum age, 2 yr.

• Administer two doses of MCV4 at least 8 wk apart, children aged 2-10 yr with persistent complement component deficiency and anatomic or functional asplenia, and one dose every 5 yr thereafter.

• Persons with human immunodeficiency virus (HIV) infection who are vaccinated with MCV4 should receive two doses at least 8 wk apart.

• Administer one dose of MCV4 to children aged 2-10 yr who travel to countries with highly endemic or epidemic disease and during outbreaks caused by a vaccine serogroup.

• Administer MCV4 to children at continued risk for meningococcal disease who were previously vaccinated with MCV4 or meningococcal polysaccharide vaccine after 3 yr if first dose was administered at age 2-6 yr.

¹ Hepatitis B vaccine (HepB) (minimum age, birth).

At birth:

^•Administer monovalent HepB to all newborns before hospital discharge.

^•If mother is hepatitis B surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hr of birth.

^•If mother’s HBsAg status is unknown, administer HepB within 12 hours of birth. Determine mother’s HBsAg status as soon as possible and, if HBsAg-positive, administer HBIG (no later than age 1 wk).

Doses following the birth dose:

^•The second dose should be administered at age 1 or 2 mo. Monovalent HepB should be used for doses administered before age 6 wk .

^•Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg 1-2 mo after completion of at least three doses of the HepB series, at age 9-18 mo (generally at the next well-child visit).

^•Administration of four doses of HepB-infants is permissible when a combination vaccine containing HepB is administered after the birth dose.

^•Infants who did not receive a birth dose should receive three doses of HepB on a schedule of 0, 1, and 6 mo.

^•The final (third or fourth) dose in the HepB series should be administered no earlier than age 24 wk.

Rotavirus vaccine (RV) (minimum age, 6 wk).

^•Administer first dose at age 6-14 wk (maximum age, 14 wk, 6 days). Vaccination should not be initiated for infants aged 15 wk, 0 days or older.

^•The maximum age for the final dose in the series is 8 mo, 0 days.

^•If Rotarix is administered at ages 2 and 4 mo, a dose at 6 mo is not indicated.

³ Diptheria and tetanus toxides and acellular perfusion vaccine (DTaP) (minimum age, 6 wk).

^•The fourth dose may be administered as early as age 12 mo, provided at least 6 mo have elapsed since the third dose.

⁴ Hemophilus influenzae type b-conjugate vaccine (Hib) (minimum age, 6 wk).

^•If PRP-OMP (PedvaxHIB or Comvax [HepB-Hib]) is administered at ages 2 and 4 mo, a dose at age 6 mo is not indicated.

^•Hiberix should not be used for doses at ages 2, 4, or 6 mo for the primary series but can be used as the final dose in children aged 12 mo-4 yr.

⁵ Pneumococcal vaccine (minimum age, 6 wk for pneumococcal conjugate vaccine [PCV]; 2 yr for pneumococcal polysaccharide vaccine [PPSV]).

^•A PCV series begun with 7-valent PCV (PCV7) should be completed with 13-valent PCV (PCV13).

^•A single supplemental dose of PCV13 is recommended for all children aged 14-59 mo who have received an age-appropriate series of PCV7.

^•A single supplemental dose of PCV13 is recommended for all children aged 60-71 mo with underlying medical conditions who have received an age-appropriate series of PCV7.

^•The supplemental dose of PCV13 should be administered at least 8 wk after the previous dose of PCV7. See MMWR 2010:59(No. RR-11).

^•Administer PPSV at least 8 wk after last dose of PCV to children aged 2 yr or older with certain underlying medical conditions, including a cochlear implant.

⁶ Inactivated poliovirus vaccine (IPV) (minimum age, 6 wk).

^•If 4 or more doses are administered prior to age 4 yr an additional dose should be administered at age 4-6 yr.

^•The final dose in the series should be administered on or after the fourth birthday and at least 6 mo following the previous dose.

⁷ Influenza vaccine (seasonal); (minimum age, 6 mo for trivalent inactivated influenza vaccine [TIV]; 2 yr for live attenuated influenza vaccine [LAIV]).

^•For healthy children aged 2 yr and older (i.e., those who do not have underlying medical conditions that predispose them to influenza complications), LAIV or TIV may be used, except that LAIV should not be given to children aged 2-4 yr who have had wheezing in the past 12 mo.

^•Administer two doses (separated by at least 4 wk) to children aged 6 mo-8 yr who are receiving seasonal influenza vaccine for the first time or who were vaccinated for the first time during the previous influenza season but only received one dose.

^•Children aged 6 mo-8 yr who received no doses of monovalent 2009 H1N1 vaccine should receive two doses of 2010–2011 seasonal influenza vaccine.

⁸ Measles, mumps, and rubella vaccine (MMR) (minimum age, 12 mo). See MMWR 2010;59(No. RR-8):33–34.

^•The second dose may be administered before age 4 yr, provided at least 4 wk have elapsed since the first dose.

ⁱVaricella vaccine (minimum age, 12 mo).

^•The second dose may be administered before age 4 yr, provided at least 3 mo have elapsed since the first dose.

^•For children aged 12 mo-12 yr, the recommended minimum interval between doses is 3 mo. However, if the second dose was administered at least 4 wk after the first dose, it can be accepted as valid.

⁹ Varicella vaccine (minimum age, 12 mo).

^•The second dose may be administered before age 4 yr, provided at least 3 mo have elapsed since the first dose.

¹⁰ Hepatitis A vaccine (HepA) (minimum age, 12 mo).

^•Administer two doses at least 6 mo apart.

^•HepA is recommended for children >23 mo who live in areas in which vaccination programs target older children, who are at increased risk for infection, or for whom immunity against hepatitis A is desired.

From Centers for Disease Control: www.cdc.gov/vaccines

Immunization Schedules (www.cdc.gov/vaccines) Retrieved October 31, 2011.

Centers for Disease Control: ___________Prevention of Pneumococcal Disease Among Infants and Children — Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine

December 10, 2010 / 59(RR11);1-18 MMWR Morb Mortal Wkly Rep 59(RR-11) 2010; and

Prevention and Control of Influenza with Vaccines

Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010

August 6, 2010 / 59(rr08);1-62 Centers for Disease Control: MMWR Morb Mortal Wkly Rep 59(RR-8):33–34, 2010.

Table 16-3A

Vaccine	Age (yr)
Vaccine	7-10	11-12	13-16
Tetanus, diphtheria, pertussis (Tdap)¹	1 dose, if indicated	Tdap¹	Tdap¹
Human papillomavirus (HPV)2	See footnote.²	3 doses	Complete 3-dose series
Meningococcal (MCV4)³	See footnote.³	1 dose	MCV4³

¹ Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap, minimum age, 10 yr for Boostrix and 11 yr for Adacel).

• Persons aged 11-18 yr who have not received Tdap should receive a dose followed by Td booster doses every 10 yr thereafter.

• Persons aged 7-10 yr who are not fully immunized against pertussis (including those never vaccinated or with unknown pertussis vaccination status) should receive a single dose of Tdap. Refer to the catch-up schedule if additional doses of tetanus and diphtheria toxoid–containing vaccine are needed.

• Tdap can be administered regardless of the interval since the last tetanus and diphtheria toxoid–containing vaccine.

² Human papillomavirus (HPV) vaccine. HPV4 (Gardasil) and HPV2 (Cervarix). (minimum age, 9 yr).

• Either HPV4 or HPV2 is recommended in a three-dose series for females aged 11 or 12 yr. HPV4 is recommended in a three-dose series for males aged 11 or 12 yr.

• The vaccine series can be started beginning at age 9 yr.

• Administer the second dose 1 to 2 mo after the first dose and the third dose 6 mo after the first dose (at least 24 wk after the first dose).

• See MMWR 2010;59:626-32, available at http://www.cdc.gov/mmwr/pdf/wk/mm5920.pdf

³ Meningococcal conjugate vaccine/MCV4, quadrivalent (minimum age, 2 yr).

• Administer MCV4 at age 11-12 yr with a booster dose at age 16 yr.

• Administer one dose at age 13-18 yr if not previously vaccinated.

• Persons who received first dose at age 13-15 yr should receive a booster dose at age 16-18 yr with a minimum interval of at least 8 wk after the preceding dose.

• If the first dose is administered at age 16 yr or older, a booster dose is not needed.

• Administer two doses at least 8 wk apart to previously unvaccinated persons with persistent complement component deficiency and anatomic or functional asplenia, and one dose every 5 yr thereafter.

• Adolescents aged 11-18 with human immunodeficiency virus (HIV) infection should receive a two-dose primary series of MCV4, at least 8 wk apart.

• See MMWR 2011;60:72-76, available at http://www.cdc.gov/mmwr/pdf/wk/mm6003.pdf and Vaccines for Children Program.

Reference: www.cdc.gov/vaccines, retrieved October 1, 2012.

From Centers for Disease Control: Vaccines and immunizations, 2012 (www.cdc.gov/vaccines).

Table 16-3B

Buy Membership for Allergy and Immunology Category to continue reading. Learn more here

Vaccine	Age: 7-18 yr
Influenza4	Yearly for all children
Pneumococcal (PCV13)5	See footnote.5
Hepatitis A (Hep A)6	Complete 2-dose series
Hepatitis (Hep B)7	Complete 3-dose series